Drug intelligence / Profile preview

Dipep

Development stage: Preclinical
Lead developer: Artery Therapeutics
Modality: Peptides
Administration: Oral

Overview

**Dipep** is an investigational Artery Therapeutics peptide candidate being developed for diabetes-generated cardiovascular disease. It is described in the company's pipeline as an apolipoprotein E-derived peptide and ATP-binding cassette subfamily A member 1 agonist intended to modulate cellular lipid handling and cholesterol efflux. The program is intended to address cardiometabolic consequences of diabetes through ABCA1-mediated effects on lipid transport and related vascular biology.

Targets

ABCA1 (ATP-binding cassette transporter A1)

Beyond the preview

Go deeper on Dipep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dipep.

Explore the full profile